[en] PURPOSE: This work aims at comparing the dosimetric possibilities of 125I or 192Ir prostate brachytherapy (Bt) as a boost to external beam radiotherapy in the treatment of locally advanced adenocarcinoma. METHODS AND MATERIALS: From 1/1997 to 12/2002, 260 patients were treated. Until 12/2001 a low dose rate (LDR) treatment with 192Ir wires was used, later replaced by a high dose rate (HDR) delivered with an 192Ir stepping source technology. For the present work, we selected 40 patients including the last 20 treated, respectively, by LDR and HDR. The planning CT Scans of all these 40 patients were transferred into the 3D Prowess system for 125I permanent implants design according to the Seattle method. The reference data for dosimetric comparisons were the V100 and the prescribed dose for 192Ir as well as the dose delivered with 125I techniques to the 192Ir V100. We compared V100-150 data as well as doses to the organs at risks (OR) and cold spots (CS). RESULTS: The V100 is 85.3+/-8% for 192Ir LDR and 96+/-2% for HDR techniques (P < 0.0001). In comparison with 125I, the 192Ir LDR mode induces higher hyperdosage volumes inside the CTV but also more CS, while maximal doses to urethra and rectum are, respectively, 17 and 39% less with 125I (P < 0.0001). In comparison with the 192Ir HDR mode, 125I Bt induces higher hyperdosage volumes and slightly more CS deliberately planned around the bladder neck. If delivered doses to urethra are identical, those to the 20% anterior part of the rectum are 33% less with 125I (P < 0,0001). The 125I Bt technique was only possible in 24 out of the 40 patients studied due to pelvic bone arch interference. CONCLUSIONS: At the present time, there is no evident dosimetric superiority of one Bt method when all the criteria are taken into account. However, improving Bt techniques to implant any prostatic size could found the superiority of the 125I or permanent implants. 125I indeed allows large hyperdosage volumes inside the CTV in comparison with 192Ir HDR techniques while lowering doses to OR and minimizing CS.
Disciplines :
Oncology
Author, co-author :
Nickers, Philippe ; Université de Liège - ULiège > Département des sciences cliniques
Thissen, Benedicte ; Centre Hospitalier Universitaire de Liège - CHU > Radiothérapie
Jansen, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Radiothérapie
Deneufbourg, Jean-Marie ; Université de Liège - ULiège > Département des sciences cliniques > Radiothérapie
Language :
English
Title :
192-Ir or 125-I Prostate Brachytherapy as a Boost to External Beam Radiotherapy in Locally Advanced Prostatic Cancer: A Dosimetric Point of View
Alternative titles :
[fr] brachythérapie de prostate à l'Iridium 192 ou l'Iode 125
D.G. Brachman, T. Thomas, J. Hilbe, and D.C. Beyer Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumours in 2222 patients: results from a single practice Int J Radiat Oncol Biol Phys 48 2000 111 117
C. Charra-Brunaud, I.C. Hsu, V. Weinberg, and J. Pouliot Analysis of interaction between number of implant catheters and dose-volume histograms in prostate high- dose-rate brachytherapy using a computer model Int J Radiat Oncol Biol Phys 56 2003 586 591
A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer J Am Med Assoc 280 1998 969 974
M. Dattoli, K. Wallner, and R. Sorace 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma Int J Radiat Oncol Biol Phys 35 1996 875 879
A. Dosoretz, R. Stock, J. Cesaretti, and N. Stone Role of external beam radiation and hormonal therapy in low, intermediate, and high risk patients treated with permanent radioactive seed implantation Int J Radiat Oncol Biol Phys 57 S 2003 227
A. Dutreix, and G. Marinello The paris system B. Pierquin J.F. Wilson D. Chassagne Modern brachytherapy 1987 Masson publishing USA Paris, France 25 42
J.F. Fowler, R.J. Chappell, and M.A. Ritter Is α/β for prostate tumors really low ? Int J Radiat Oncol Biol Phys 50 2001 1021 1031
R.M. Galalae, G. Kovacs, and J. Schultze Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer Int J Radiat Oncol Biol Phys 52 2002 81 90
R.M. Galalae, A. Martinez, and T. Mate Long-term outcome by risk factors using conformal high dose rate (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer Int J Radiat Oncol Biol Phys 58 2004 1048 1055
D.Y. Gelblum, L. Potters, R. Ashley, R. Waldbaum, X.H. Wang, and S. Leibel Urinary morbidity following ultrasound-guided transperineal prostate seed implantation Int J Radiat Oncol Biol Phys 45 1999 59 67
P.D. Grimm, J.C. Blasko, and H. Ragde Ultrasound guided transperineal implantation of iodine-125 and palladium-103 for the treatment of early-stage prostate cancer: technical concepts in planning, operative technique, and evaluation P.F. Schellhammer New techniques in prostatic surgery 1995 Saunders Philadelphia 113 126
ICRU REPORT 38. Dose and volume specification for reporting intracavitary therapy in gynecology; 1985.
G. Kovacs, R. Potter, and T. Loch GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer Radiother Oncol 74 2005 137 148
W.R. Lee, J. Moughan, J. Owen, and M. Zelefsky The 1999 patterns of care survey of radiation therapy in localized prostate cancer. A comprehensive survey of prostate brachytherapy in the United States Int J Radiat Oncol Biol Phys 57 Suppl. 2 2003 226
C.C. Ling, J. Humm, and S. Larson Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality Int J Radiat Oncol Biol Phys 47 2000 551 560
A.A. Martinez, G. Gustafson, and J. Gonzalez Dose escalation using conformal high dose rate brachytherapy improves outcome in unfavorable prostate cancer Int J Radiat Oncol Biol Phys 53 2002 316 327
G.S. Merrick, W.M. Butler, R.W. Galbreath, and J.H. Lief Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer Int J Radiat Oncol Biol Phys 51 2001 41 48
S. Nag, D. Beyer, J. Friedland, P. Grimm, and R. Nath American brachytherapy society recommendations for transperineal permanent brachytherapy of prostate cancer Int J Radiat Oncol Biol Phys 44 1999 789 799
P. Nickers, L. Coppens, M. Beauduin, M. Darimont, J. de Leval, and J.M. Deneufbourg Feasibility study combining low dose rate 192 Ir brachytherapy and external beam radiotherapy aiming at delivering 80-85 Gy to prostatic adenocarcinoma Radiother Oncol 55 2000 41 47
P. Nickers, E. Lenaerts, B. Thissen, and J.M. Deneufbourg Does inverse planning applied to Iridium192 high dose rate prostate brachytherapy improve the optimization of the dose afforded by the Paris system ? Radiother Oncol 74 2005 131 136
J.E. Sylvester, J.C. Blasko, P.D. Grimm, R. Meier, and J.A. Malmgren Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience Int J Radiat Oncol Biol Phys 57 2003 944 952
M.D. Terk, R.G. Stock, and N.N. Stone Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate J Urol 160 1998 1379 1382
J.Z. Wang, and X.A. Li Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose Med Phys 30 2003 34 40
